Cover Image
市場調查報告書

慢性阻塞性肺病(COPD) - 開發中產品分析

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 264708
出版日期 內容資訊 英文 577 Pages
訂單完成後即時交付
價格
Back to Top
慢性阻塞性肺病(COPD) - 開發中產品分析 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 577 Pages
簡介

慢性阻塞性肺病(COPD)是由於肺的呼氣吸氣不完全,呼吸困難造成的肺部疾病。由於空氣流入肺臟受阻,咳嗽,疲勞感,胸部疼痛的症狀便會與時俱增,同時也增加了併發症。第一個風險要素是吸煙,但化學物質及大氣污染等也是COPD惡化的要因。可以禁煙及服用其他治療藥來控制病情。

本報告提供慢性阻塞性肺病(COPD)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

慢性阻塞性肺病(COPD)概要

治療藥的開發

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

開發中的產品:各企業

調查中的產品:各大學/實驗室

開發治療藥的企業

治療藥的評估

開發中產品的最新趨勢

暫停開發的產品

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8528IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 13, 40, 29, 81, 25 and 5 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively for Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Chronic Obstructive Pulmonary Disease (COPD) Overview
  • Therapeutics Development
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance
  • Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies
  • Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes
  • Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
  • Drug Profiles
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
  • Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2016
  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Abeona Therapeutics, Inc. , H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinky Biopharma, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alteogen Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amakem NV, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angion Biomedica Corp., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asubio Pharma Co., Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axikin Pharmaceuticals, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bayer AG, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Beech Tree Labs, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corporation, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biotie Therapies Corp., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings PLC, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Limited, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Limited, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Elsalys Biotech SAS, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by enGene, Inc, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics, LLC, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by InMed Pharmaceuticals Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Innate Pharma S.A., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Invion Limited, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medestea Research & Production S.p.A., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Merck & Co., Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mereo Biopharma Group Plc, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Meridigen Biotech Co., Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Microbion Corporation, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novartis AG, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Odan Laboratories Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by OPKO Health, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orion Oyj, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pfizer Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by PharmaLundensis AB, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pharmaxis Limited, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pila Pharma AB, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Polyphor Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Promedior, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Proteostasis Therapeutics, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmagen Therapeutics LLP, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmatrix, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Re-Pharm Limited, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Recipharm AB, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respira Therapeutics Inc, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respiratorius AB, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by rEVO Biologics, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SATT North SAS, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Selvita S.A., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Seoul Pharma Co., Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stelic Institute & Co., Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Synovo GmbH, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by TGV-Laboratories, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Therabron Therapeutics, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theravance Biopharma, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by U.S. Stem Cell, Inc., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Unizyme Laboratories A/S, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vectura Group Plc, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Verona Pharma Plc, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yuhan Corporation, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Zambon Company S.p.A., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..1), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..2), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..3), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..4), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..5), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..6), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..7), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..8), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..9), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..10), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..11), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..12), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..13), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..14), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..15), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..16), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..17), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..18), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..19), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..20), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..21), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..22), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..23), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..1), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..2), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..3), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..4), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..5), H2 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..6), H2 2016

List of Figures

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2016
  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top